Marketresearch.biz reports that the Corticosteroid Eyedrops Market was valued at USD 17.5 billion in 2023. It is expected to reach USD 31.8 billion by 2033, with a CAGR of 6.3% during the forecast period from 2024 to 2033.Overview of the Corticosteroid Eyedrops MarketThe Corticosteroid Eyedrops Market is expanding,.
PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Dritschilo is a renowned educator, inventor, translational scien
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden - - 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 - - Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection - - Ixo-vec continues to be generally wel